胰高血糖素市场 - 按产品类型（注射剂、吸入剂）、应用（低血糖、诊断辅助、胃肠道疾病）、配销通路（医院药房、零售药房、线上药房） - 全球预测（2024 - 2032）

由于自我管理设备的蓬勃发展，2024 年至 2032 年间，全球胰高血糖素市场的复合年增长率将超过 5.9%。这些设备易于使用，使患者能够独立管理低血糖事件，从而提高便利性和依从性。自我管理的转变减少了对立即医疗救助的需求，这对于血糖水平突然下降的糖尿病患者特别有益。

2023 年 8 月，Xeris Pharmaceuticals Inc. 报告称，78% 的商业保险和医疗保险受益人可以不受限制地使用 Gvoke HypoPen，这是一种用于治疗严重低血糖的胰高血糖素注射剂。直观且可靠的输送系统的发展促进了这一趋势，该系统确保准确的剂量并减少与紧急胰高血糖素使用相关的焦虑。对胰高血糖素产品的需求将大幅增加。

整个胰高血糖素市场根据产品类型、应用、配销通路和地区进行分类。

从2024年到2032年，吸入剂细分市场将呈现大幅复合年增长率，因为其非侵入性且方便的给药方式对注射不舒服的患者很有吸引力。吸入胰高血糖素可快速吸收并起效，使其成为低血糖的有效紧急治疗方法。此外，它的易用性确保了对传统注射方法有困难的患者（包括儿童和老年人）更好的依从性。药物传递技术的进步增强了患者体验和可及性，扩大了吸入领域不断增长的需求。

到2032 年，诊断辅助领域将占据重要的胰高血糖素市场份额。需求正在增加。胰高血糖素用于放鬆胃肠道平滑肌，促进更清晰的影像结果并有助于诊断准确性。它在暂时抑制胰岛素分泌方面的有效性在某些诊断测试中也被证明是有价值的。随着医疗程序的发展和影像技术的进步，由于胰高血糖素在增强诊断能力和患者护理结果方面的作用，对胰高血糖素作为诊断辅助剂的需求持续增长。

从2024年到2032年，北美胰高血糖素市场将呈现健康的复合年增长率。城市化进程的加速和久坐的生活方式导致糖尿病和相关併发症的盛行率升高，因此需要有效的管理解决方案，例如胰高血糖素。医疗基础设施的改善和可支配收入的增加正在扩大糖尿病护理产品的取得范围。旨在提高公众健康意识和糖尿病管理的政府措施也在刺激市场成长方面发挥着至关重要的作用。这些因素有助于亚太地区对胰高血糖素的需求不断增长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
  • 糖尿病盛行率上升
  • 增加研发活动
  • 对非注射紧急肝醣的需求不断增长
  • 製药业的进步
  • 产业陷阱与挑战
  • 缺乏消费者意识
  • 严格的监管框架
• 成长潜力分析
• 监管环境
• 技术景观
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 竞争定位矩阵
• 公司矩阵分析
• 战略展望矩阵

第 5 章：市场估计与预测：按产品类型，2021 - 2032 年

• 主要趋势
• 可注射
• 吸入

第 6 章：市场估计与预测：按应用分类，2021 - 2032

• 主要趋势
• 低血糖
• 诊断辅助
• 胃肠道疾病
• 心臟休克
• 其他应用

第 7 章：市场估计与预测：按配销通路划分，2021 - 2032 年

• 主要趋势
• 医院药房
• 零售药局
• 网路药局

第 8 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿联酋
  • 中东和非洲其他地区

第 9 章：公司简介

• Amgen Inc.
• Avalon Pharma Private Limited
• Bachem Holding AG
• Eli Lilly and Company
• Fresenius SE & Co. KGaA
• Fujifilm Holdings Corporation
• Novo Nordisk A/S
• Pfizer, Inc.
• Svar Life Science
• Taj Pharmaceuticals Ltd.
• Xeris Biopharma Holdings, Inc.

Global Glucagon Market will exhibit over 5.9% CAGR between 2024 and 2032, catapulted by the thriving adoption of self-administration devices. These devices, designed for ease of use, empower patients to manage hypoglycemic episodes independently, enhancing convenience and compliance. The shift toward self-administration reduces the need for immediate medical assistance, which is particularly beneficial for diabetic patients who experience sudden drops in blood sugar levels.

In August 2023, Xeris Pharmaceuticals Inc. reported that 78% of commercially insured and Medicare beneficiaries had unrestricted access to Gvoke HypoPen, a glucagon injection for severe hypoglycemia treatment. This trend is encouraged by the development of intuitive and reliable delivery systems, which ensure accurate dosing and reduce the anxiety associated with emergency glucagon use. The demand for glucagon products will upsurge significantly.

The overall glucagon market is categorized based on product type, application, distribution channel, and region.

From 2024 to 2032, the inhalation segment will depict substantial CAGR growth due to its non-invasive and convenient delivery method, which is appealing to patients who are uncomfortable with injections. Inhalation glucagon offers rapid absorption and onset of action, making it an effective emergency treatment for hypoglycemia. Additionally, its ease of use ensures better adherence among patients, including children and the elderly, who struggle with traditional injection methods. This advancement in drug delivery technology enhances patient experience and accessibility, amplifying the increasing demand in the inhalation segment.

The diagnostic aid segment will possess a significant glucagon market share by 2032. The demand for glucagon in the diagnostic aid segment is increasing owing to its utility in various medical procedures such as gastrointestinal motility studies and imaging scans. Glucagon is used to relax the smooth muscles of the gastrointestinal tract, facilitating clearer imaging results and aiding in diagnostic accuracy. Its effectiveness in temporarily inhibiting insulin secretion also proves valuable in certain diagnostic tests. As medical procedures evolve and imaging technologies advance, the demand for glucagon as a diagnostic aid continues to grow, directed by its role in enhancing diagnostic capabilities and patient care outcomes.

From 2024 to 2032, North America glucagon market will demonstrate a healthy CAGR. Increasing urbanization and the adoption of a more sedentary lifestyle contribute to a higher prevalence of diabetes and related complications, necessitating effective management solutions such as glucagon. Improving healthcare infrastructure and rising disposable incomes are expanding access to diabetes care products. Government initiatives aimed at improving public health awareness and diabetes management also play a crucial role in stimulating market growth. These factors aid the growing demand for glucagon in the Asia Pacific.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
  • 3.2.2 Rising prevalence of diabetes
  • 3.2.3 Increasing research & development activities
  • 3.2.4 Growing demand for non-injectable emergency glycogen
  • 3.2.5 Advancements in pharmaceutical sector
  • 3.2.6 Industry pitfalls & challenges
  • 3.2.7 Lack of consumer awareness
  • 3.2.8 Stringent regulatory framework
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive positioning matrix
• 4.4 Company matrix analysis
• 4.5 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Injectable
• 5.3 Inhalation

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Hypoglycemia
• 6.3 Diagnostic aid
• 6.4 Gastrointestinal disorders
• 6.5 Cardiogenic shock
• 6.6 Other applications

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacies
• 7.3 Retail pharmacies
• 7.4 Online pharmacies

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Amgen Inc.
• 9.2 Avalon Pharma Private Limited
• 9.3 Bachem Holding AG
• 9.4 Eli Lilly and Company
• 9.5 Fresenius SE & Co. KGaA
• 9.6 Fujifilm Holdings Corporation
• 9.7 Novo Nordisk A/S
• 9.8 Pfizer, Inc.
• 9.9 Svar Life Science
• 9.10 Taj Pharmaceuticals Ltd.
• 9.11 Xeris Biopharma Holdings, Inc.